Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass [clinicaltrials:NCT01433302]
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass [clinicaltrials:NCT01433302]
Bio2RDF identifier
NCT01433302
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT01433302
identifiers.org URI
actual enrollment [clinicaltrials_vocabulary:actual-enrollment]
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
The goal of this clinic ...... e how well the surgery works.
brief title [clinicaltrials_vocabulary:brief-title]
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
collaborator [clinicaltrials_vocabulary:collaborator]
completion date [clinicaltrials_vocabulary:completion-date]
2014-03-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
If you choose to take p ...... l be enrolled at MD Anderson.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2011-09-08T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
Breast cancer
Genitourinary cancer
Gynecological cancer
Inflammatory Response
Inflammatory proteins
Lab collections
Lymphatico-venous Bypass Surgery
Lymphedema
Malignant Female Reproductive System Neoplasm
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2015-05-05T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT01433302
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Determination of the Effect of ...... Responses and Tissue Fibrosis
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2014-03-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2012-03-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2015-05-01T00:00:00Z
identifier
clinicaltrials:NCT01433302
title
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
@en
type
label
Inflammatory Response and Tiss ...... s [clinicaltrials:NCT01433302]
@en